CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks
L Hovhannisyan, C Riether, DM Aebersold, M Medová… - Molecular cancer, 2023 - Springer
CAR T cell-based therapies have revolutionized the treatment of hematological
malignancies such as leukemia and lymphoma within the last years. In contrast to the …
malignancies such as leukemia and lymphoma within the last years. In contrast to the …
Combination of CAR‑T cell therapy and radiotherapy: Opportunities and challenges in solid tumors
L Zhong, Y Li, TA Muluh, Y Wang - Oncology Letters, 2023 - spandidos-publications.com
Chimeric antigen receptor (CAR) T cell therapy has emerged as a new and breakthrough
cancer immunotherapy. Although CAR‑T cell therapy has made significant progress …
cancer immunotherapy. Although CAR‑T cell therapy has made significant progress …
[HTML][HTML] Bridging radiation rapidly and effectively cytoreduces high-risk relapsed/refractory aggressive B cell lymphomas prior to chimeric antigen receptor T cell …
H Hubbeling, EA Silverman, L Michaud… - … and cellular therapy, 2023 - Elsevier
Greater tumor burden before CD19-targeted chimeric antigen receptor T cell (CAR-T)
therapy predicts lower complete response rate and shorter overall survival (OS) in patients …
therapy predicts lower complete response rate and shorter overall survival (OS) in patients …
[HTML][HTML] Long-term follow-up of bridging therapies prior to CAR T-cell therapy for relapsed/refractory large B cell lymphoma
C Ladbury, S Dandapani, C Hao, M Fabros, A Amini… - Cancers, 2023 - mdpi.com
Simple Summary Bridging therapy (BT) in the form of systemic therapy (ST), radiation
therapy (RT), or combined-modality therapy (CMT) is increasingly being utilized prior to …
therapy (RT), or combined-modality therapy (CMT) is increasingly being utilized prior to …
Potential synergy between radiotherapy and CAR T-cells-a multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapy
J Fan, A Adams, N Sieg, JM Heger, P Gödel… - Radiotherapy and …, 2023 - Elsevier
Background Chimeric antigen receptor (CAR) T-cell therapy has improved the limited overall
survival (OS) of patients with intensively pretreated diffuse large B-cell lymphoma (DLBCL) …
survival (OS) of patients with intensively pretreated diffuse large B-cell lymphoma (DLBCL) …
CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas
GY Cederquist, J Schefflein, SM Devlin… - Blood …, 2024 - ashpublications.org
Chimeric antigen receptor (CAR) T-cell therapy (CART) for central nervous system
lymphoma (CNSL) is a promising strategy, yet responses are frequently not durable …
lymphoma (CNSL) is a promising strategy, yet responses are frequently not durable …
Assessing the role of radiotherapy in patients with refractory or relapsed high-grade B-cell lymphomas treated with CAR T-cell therapy
Abstract An estimated 30–40% of patients with diffuse large B cell lymphoma (DLBCL) will
either relapse or have refractory disease with first-line chemoimmunotherapy. The standard …
either relapse or have refractory disease with first-line chemoimmunotherapy. The standard …
Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange
Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening autoimmune
disorder caused by a disintegrin and metalloproteinase with thrombospondin type 1 motif …
disorder caused by a disintegrin and metalloproteinase with thrombospondin type 1 motif …
The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma
O Albanyan, J Chavez, J Munoz - Therapeutic advances in …, 2022 - journals.sagepub.com
For approximately three decades, autologous hematopoietic cell transplantation (auto-HCT)
has been the standard of care for patients with relapsed/refractory (R/R) diffuse large B-cell …
has been the standard of care for patients with relapsed/refractory (R/R) diffuse large B-cell …
[HTML][HTML] Biomimetic bright optotheranostics for metastasis monitoring and multimodal image-guided breast cancer therapeutics
Nanoparticle formulations blending optical imaging contrast agents and therapeutics have
been a cornerstone of preclinical theranostic applications. However, nanoparticle-based …
been a cornerstone of preclinical theranostic applications. However, nanoparticle-based …